Virax End Period Cash Flow from 2010 to 2024

VRAX Stock  USD 1.94  0.06  3.19%   
Virax Biolabs End Period Cash Flow yearly trend continues to be fairly stable with very little volatility. End Period Cash Flow will likely drop to about 2.9 M in 2024. During the period from 2010 to 2024, Virax Biolabs End Period Cash Flow regression line of annual values had r-squared of  0.30 and arithmetic mean of  1,071,205. View All Fundamentals
 
End Period Cash Flow  
First Reported
2010-12-31
Previous Quarter
3.6 M
Current Value
2.9 M
Quarterly Volatility
2.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Virax Biolabs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Virax Biolabs' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 97.9 K or Interest Expense of 28.3 K, as well as many indicators such as Price To Sales Ratio of 8.96, Dividend Yield of 0.0 or PTB Ratio of 0.29. Virax financial statements analysis is a perfect complement when working with Virax Biolabs Valuation or Volatility modules.
  
Check out the analysis of Virax Biolabs Correlation against competitors.

Latest Virax Biolabs' End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Virax Biolabs Group over the last few years. It is Virax Biolabs' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Virax Biolabs' overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

Virax End Period Cash Flow Regression Statistics

Arithmetic Mean1,071,205
Geometric Mean64,159
Coefficient Of Variation238.44
Mean Deviation1,678,533
Median22,609
Standard Deviation2,554,138
Sample Variance6.5T
Range9.3M
R-Value0.55
Mean Square Error4.9T
R-Squared0.30
Significance0.03
Slope313,924
Total Sum of Squares91.3T

Virax End Period Cash Flow History

20242.9 M
20233.6 M
20229.4 M
202121.8 K
202017.6 K

About Virax Biolabs Financial Statements

Virax Biolabs investors use historical fundamental indicators, such as Virax Biolabs' End Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Virax Biolabs. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow3.6 M2.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Virax Stock Analysis

When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.